Sana 10-Q: Going-Concern Warning With $121.7M Cash, Q3 Profit Is Non-Cash
SANA is trading near its 52-week low of $2.22 (9.9% above the low).
Summary
Sana's Q3 10-Q carries a going-concern warning: $121.7 million in cash against a $108.9 million nine-month operating burn, with the quarter's $20.4 million profit coming entirely from non-cash fair-value gains rather than operations.
Key Events · Earnings and Guidance · SANA
-
Going-Concern Doubt Disclosed
Management determined current capital resources may not be sufficient to fund planned operations for at least one year from the date of the Quarterly Report, and there is substantial doubt about the ability to continue as a going concern.
-
Q3 Profit Is Non-Cash
Q3 2026 net income of $20.4 million, or $0.07 per share, was driven by a $63.4 million non-cash gain on success payment and contingent consideration liabilities, $55.5 million of it from the August 2026 Cobalt amendment — not operating performance.
-
Cash Down to $121.7 Million
Cash, cash equivalents and marketable securities were $121.7 million at September 30, 2026, versus $138.4 million at December 31, 2025, after $108.9 million of nine-month operating cash use offset by $93.5 million of financing proceeds.
-
ATM Untouched, Financing Likely
No shares were sold under the $150.0 million TD Cowen at-the-market facility in Q3 2026, leaving the full program available as the company addresses the funding gap.
Analysis · SANA · Life Sciences
The headline $20.4 million Q3 profit is an accounting artifact, not operating performance. It stems from a $63.4 million non-cash gain on remeasuring success payment and contingent consideration liabilities, $55.5 million of which came from the August 2026 Cobalt amendment. Strip that out and the underlying business still lost money: the nine-month net loss was $90.4 million and operating cash burn was $108.9 million. The real story is the going-concern statement. With $121.7 million in cash and securities at September 30, management says resources may not fund planned operations for at least one year. That puts a financing — likely equity, given the $150.0 million ATM is untouched — on the table within roughly the next year, and dilution risk is live.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SANA was trading at $2.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $700.5M. The 52-week trading range was $2.22 to $5.49. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.